Challenging surgical treatment of giant retroperitoneal liposarcoma: A case report

Wei,Xiaoyi; Qin,Yujie; Ouyang,Song; Qian,Jun; Tu,Song; Yao,Jiaxi

doi:10.3892/ol.2022.13434

Challenging surgical treatment of giant retroperitoneal liposarcoma: A case report

Authors:
- Xiaoyi Wei
- Yujie Qin
- Song Ouyang
- Jun Qian
- Song Tu
- Jiaxi Yao
View Affiliations

Affiliations: Department of Urology, Hexi University Affiliated Zhangye People's Hospital, Zhangye, Gansu 734000, P.R. China, Department of Endoscopy Center, Hexi University Affiliated Zhangye People's Hospital, Zhangye, Gansu 734000, P.R. China, Department of Urology, First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, Xinjiang 830000, P.R. China, Institute of Urology, Hexi University, Zhangye, Gansu 734000, P.R. China, Department of Urology, Hexi University Affiliated Zhangye People's Hospital, Zhangye, Gansu 734000, P.R. China
Published online on: July 15, 2022 https://doi.org/10.3892/ol.2022.13434
Article Number: 314
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liposarcoma is a rare malignant tumor type and surgical resection is the gold standard treatment. The present study reported on the case of a 51‑year‑old woman who presented with a mass in the left upper abdomen. Computed tomography revealed a 32‑cm giant retroperitoneal liposarcoma. Complete tumor resection was performed without the removal of other organs. Postoperative pathological examination indicated retroperitoneal well‑differentiated liposarcoma and immunohistochemistry revealed S‑100(‑), MDM2(+), vimentin(+), CDK4(+), p16(+) and STAT6(+) results. The patient recovered well after the surgery. Complete tumor resection during the first surgery is key to cure liposarcoma. The present case report will be helpful for clinical oncologists to fully understand giant retroperitoneal liposarcoma and treat it accordingly.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Ray-Coquard I, Serre D, Reichardt P, Martin-Broto J and Bauer S: Options for treating different soft tissue sarcoma subtypes. Future Oncol. 14:25–49. 2018. View Article : Google Scholar
3	Thway K: Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review. Semin Diagn Pathol. 36:112–121. 2019. View Article : Google Scholar
4	Mansfield SA, Pollock RE and Grignol VP: Surgery for abdominal well-differentiated liposarcoma. Curr Treat Options Oncol. 19:12018. View Article : Google Scholar
5	Kallen ME and Hornick JL: The 2020 WHO classification: What's new in soft tissue tumor pathology? Am J Surg Pathol. 45:e1–e23. 2021. View Article : Google Scholar
6	Improta L, Tzanis D, Bouhadiba T, Abdelhafidh K and Bonvalot S: Overview of primary adult retroperitoneal tumours. Eur J Surg Oncol. 46:1573–1579. 2020. View Article : Google Scholar
7	Bock S, Hoffmann DG, Jiang Y, Chen H and Il'yasova D: Increasing incidence of liposarcoma: A population-based study of National surveillance databases, 2001–2016. Int J Environ Res Public Health. 17:27102020. View Article : Google Scholar
8	Herrera-Almario G, Cabrera LF, Londono-Schimmer EE and Pedraza M: Giant retroperitoneal liposarcoma surgical management. Ann R Coll Surg Engl. 104:e54–e56. 2022. View Article : Google Scholar
9	Qiao Z, Zhan R, Pang Y and Wu J: Giant retroperitoneal dedifferentiated liposarcoma in an old man. Asian J Surg. 44:1076–1078. 2021. View Article : Google Scholar : PubMed/NCBI
10	Wu YX, Liu JY, Liu JJ, Yan P, Tang B, Cui YH, Zhao YL, Shi Y, Hao YX, Yu PW and Qian F: A retrospective, single-center cohort study on 65 patients with primary retroperitoneal liposarcoma. Oncol Lett. 15:1799–1810. 2018.
11	Lee ATJ, Thway K, Huang PH and Jones RL: Clinical and molecular spectrum of liposarcoma. J Clin Oncol. 36:151–159. 2018. View Article : Google Scholar
12	Yao JX, Chen X, Zhu YJ, Wang H, Hu XY and Guo JM: Prognostic value of vimentin is associated with immunosuppression in metastatic renal cell carcinoma. Front Oncol. 10:11812020. View Article : Google Scholar
13	Cheung KT, Mitchell C and Wong E: Retroperitoneal liposarcoma in a nonagenarian. Autops Case Rep. 11:e20202242020. View Article : Google Scholar : PubMed/NCBI
14	Wang Q, Juan YH, Li Y, Xie JJ, Liu H, Huang H, Liu Z, Zheng J, Saboo US, Saboo SS and Liang C: Multidetector computed tomography features in differentiating exophytic renal angiomyolipoma from retroperitoneal liposarcoma: A Strobe-compliant observational study. Medicine (Baltimore). 94:e15212015. View Article : Google Scholar : PubMed/NCBI
15	Mascarenhas MRM, Mutti LA, Paiva JMG, Enokihara MMSES, Rosa IP and Enokihara MY: Giant atypical lipoma. An Bras Dermatol. 92:546–549. 2017. View Article : Google Scholar
16	Haddox CL and Riedel RF: Recent advances in the understanding and management of liposarcoma. Fac Rev. 10:12021. View Article : Google Scholar : PubMed/NCBI
17	Bonvalot S, Gronchi A, Le Pechoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, et al: Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 21:1366–1377. 2020. View Article : Google Scholar
18	Crago AM and Dickson MA: Liposarcoma: Multimodality management and future targeted therapies. Surg Oncol Clin N Am. 25:761–773. 2016. View Article : Google Scholar : PubMed/NCBI